Sanofi (SNY) Competitors $46.86 +0.24 (+0.51%) Closing price 04:00 PM EasternExtended Trading$46.98 +0.12 (+0.26%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNY vs. NVS, AZN, NVO, GSK, TAK, ARGX, ONC, INSM, BNTX, and TEVAShould you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Novartis (NVS), AstraZeneca (AZN), Novo Nordisk A/S (NVO), GSK (GSK), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry. Sanofi vs. Its Competitors Novartis AstraZeneca Novo Nordisk A/S GSK Takeda Pharmaceutical argenex BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Novartis (NYSE:NVS) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations. Do institutionals and insiders hold more shares of NVS or SNY? 13.1% of Novartis shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor NVS or SNY? In the previous week, Novartis had 12 more articles in the media than Sanofi. MarketBeat recorded 29 mentions for Novartis and 17 mentions for Sanofi. Novartis' average media sentiment score of 1.05 beat Sanofi's score of 0.75 indicating that Novartis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 21 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 8 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, NVS or SNY? Novartis has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Is NVS or SNY a better dividend stock? Novartis pays an annual dividend of $2.59 per share and has a dividend yield of 2.1%. Sanofi pays an annual dividend of $1.59 per share and has a dividend yield of 3.4%. Novartis pays out 37.7% of its earnings in the form of a dividend. Sanofi pays out 38.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Is NVS or SNY more profitable? Novartis has a net margin of 25.64% compared to Sanofi's net margin of 21.47%. Novartis' return on equity of 41.08% beat Sanofi's return on equity.Company Net Margins Return on Equity Return on Assets Novartis25.64% 41.08% 16.83% Sanofi 21.47%16.86%9.63% Do analysts prefer NVS or SNY? Novartis currently has a consensus target price of $120.33, indicating a potential downside of 2.08%. Sanofi has a consensus target price of $62.67, indicating a potential upside of 33.73%. Given Sanofi's stronger consensus rating and higher possible upside, analysts plainly believe Sanofi is more favorable than Novartis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novartis 3 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.00Sanofi 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20 Which has higher valuation and earnings, NVS or SNY? Novartis has higher revenue and earnings than Sanofi. Sanofi is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovartis$55.19B4.70$11.94B$6.8717.89Sanofi$45.74B2.52$6.02B$4.1611.26 SummaryNovartis beats Sanofi on 12 of the 19 factors compared between the two stocks. Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNY vs. The Competition Export to ExcelMetricSanofiLarge Cap Pharma IndustryMedical SectorNASDAQ ExchangeMarket Cap$115.07B$253.86B$5.69B$10.27BDividend Yield3.40%2.71%5.72%4.60%P/E Ratio11.2630.4275.8626.51Price / Sales2.524.42489.92165.32Price / Cash8.8213.6625.8129.89Price / Book1.4118.6312.846.32Net Income$6.02B$8.49B$3.28B$270.51M7 Day Performance-1.24%-1.30%0.22%2.15%1 Month Performance-5.85%0.35%4.61%6.35%1 Year Performance-18.26%-10.58%68.33%25.48% Sanofi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNYSanofi3.9572 of 5 stars$46.86+0.5%$62.67+33.7%-18.4%$115.07B$45.74B11.2682,878NVSNovartis2.2271 of 5 stars$128.75-0.8%$124.33-3.4%+6.6%$271.97B$50.32B18.7475,883Positive NewsAZNAstraZeneca2.9551 of 5 stars$81.56-0.2%$86.00+5.4%-0.3%$252.95B$54.07B30.6694,300Positive NewsShort Interest ↑Analyst RevisionNVONovo Nordisk A/S4.19 of 5 stars$54.30-1.7%$81.00+49.2%-59.4%$242.45B$42.12B14.9277,349Trending NewsAnalyst UpgradeShort Interest ↑Gap UpGSKGSK2.0072 of 5 stars$40.06-1.1%$37.38-6.7%-6.3%$81.58B$40.10B18.5468,629Positive NewsDividend CutTAKTakeda Pharmaceutical2.4481 of 5 stars$15.27-0.9%N/A+2.6%$48.57B$30.09B50.8847,455High Trading VolumeARGXargenex3.9623 of 5 stars$768.00+2.3%$772.84+0.6%+40.7%$47.00B$2.25B39.381,599Analyst DowngradeONCBeOne Medicines1.7569 of 5 stars$346.45+1.4%$330.89-4.5%N/A$37.97B$3.81B-200.2611,000Gap UpINSMInsmed3.3174 of 5 stars$146.68+1.1%$139.86-4.7%+91.7%$31.01B$363.71M-25.691,271Positive NewsInsider TradeBNTXBioNTech2.5137 of 5 stars$102.66-8.7%$135.80+32.3%-20.7%$24.68B$2.98B-64.166,772High Trading VolumeTEVATeva Pharmaceutical Industries2.7203 of 5 stars$19.30+1.8%$24.71+28.1%+2.7%$22.13B$16.54B-120.6136,830 Related Companies and Tools Related Companies NVS Alternatives AZN Alternatives NVO Alternatives GSK Alternatives TAK Alternatives ARGX Alternatives ONC Alternatives INSM Alternatives BNTX Alternatives TEVA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNY) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredFree: The Crypto Summit That Could Change Your LifeWall Street’s Crypto Playbook—Revealed at This Free Event If you want to understand what's really happening...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
